Oncology Medical News

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

A phase II study of intra-arterial chemotherapy of 5-fluorouracil, cisplatin, and mitomycin C for advanced nonresectable gastric cancer
Anti-Cancer Drugs, 10/15/09

Li M et al. – The best choice of chemotherapy regimen for patients with advanced gastric cancer (AGC) is still a matter of controversy.Intra-arterial infusion chemotherapy of 5-fluorouracil 1000 mg/m2, cisplatin 50 mg/m2, and mitomycin C 10 mg/m2 is a tolerated treatment modality with promising activity in patients with previously untreated AGC.

Methods

Forty-seven (95.9%) of the 49 patients assessable for response.
Efficacy and safety of intra-arterial infusion chemotherapy of 5-fluorouracil 1000 mg/m2, cisplatin 50 mg/m2, and mitomycin C 10 mg/m2 (FCM) repeated every 6 weeks, as first-line treatment for AGC evaluated

Results

4 cases of complete response and 28 cases of partial response confirmed
Median time to progression and overall survival for all patients was 8.3 months (95% CI: 6.8-9.8 months) and 14.5 months
Estimate of overall survival at 12 and 24 months was 55.1% and 18.4%
Most patients experienced neutropenia during course of therapy with 21.3% of patients for grade 3/4 neutropenia
Grade 3 stomatitis, lethargy, and palmar-plantar erythema observed in 2(4.3%), 8 (17.0%), and 1 (2.1%) patients
No grade 4 nonhematological toxicity observed
Intra-arterial infusion chemotherapy of 5-fluorouracil 1000 mg/m2, cisplatin 50 mg/m2, and mitomycin C 10 mg/m2 is tolerated treatment modality with promising activity in patients with previously untreated AGC

<< Previous
Phase II study of cisplatin plus etoposide and bevacizumab for...

Next >>
A Phase I and Pharmacokinetic Study of Oral Lapatinib...